Cone-Rod Dystrophy Market Research Report - Global Forecast till 2027

Cone Rod Dystrophy Market Research Report– By Diagnosis (ERG, Clinical History, Fundus Examination, Molecular Diagnosis), By Treatment (Tinted Lenses, Medication, Magnifying Devices), By End User (Hospitals, Ophthalmic Centers) – Global Forecast Till 2027

ID: MRFR/Pharma/3824-HCR | | Region: Global | 90 pages

Market Scenario


Cone-Rod Dystrophy is a group of related eye disorders that cause gradual loss of vision due to retinal deterioration this may lead to increasing severity or even blindness. Generally, the disorders affects the rod and cones cells present in the retina which are responsible for vision and clarity. According to NCBI, prevalence of cone-rod dystrophies is estimated to be 1 in every 40,000 cases.


According to World Health Organization, in 2014, worldwide 285 million people were estimated to be visually impaired, out of which nearly 246 million have low vision and 39 million are completely blind. Uncorrected errors are the major reasons for causing moderate and severe visual impairment. But still, 80% of the ophthalmic diseases can be cured or prevented by treatment.


There are many new low vision aids, including telescopic and magnifying lenses, providing plenty of choice for users at all stages of sight loss. This technology has also removed many barriers to education and employment. According to American Academy of Ophthalmology, more than 25% of America’s population suffer from minor or major visual complication. More than 150 million Americans use corrective eyewear and spend more than $15 billion each year on eyewear.


Ophthalmic impairment is caused due to a number of diseases like infectious diseases, genetic factor and many more, but diabetes have a major impact on the growth of the market. Diabetes is one of the important disorder responsible for causing visual impairment as it damages retinal blood vessels. According to WHO, 422 million people are suffering from diabetes and this number is increasing at the rate of 8.5%. According to the American Academy of Ophthalmology, diabetes is responsible for causing visual complication in approximately 4.5 million Americans.


This disorder can be curbed to a great extent by proper use of vitamin supplements therefore the cone rod dystrophy market is majorly effected by the Thiamine supplements. The growth of the vitamin industry is due to the increased per-capita income and increased health awareness among people. As the people are getting more aware about taking care of their health, they are giving more importance to these supplements to prevent various deficiencies. Online retailing of these supplements has further increased accessibility and has increased the customer base and it has also increased the convenience of buying which will indirectly effect the Cone Rod Dystrophy market.


Despite the lack of current treatments for cone-rod dystrophies, general eye check-ups are important. Furthermore, the people suffering from this conditions may experience other kinds of eye problems. Patients with cone rod dystrophy tend to develop cataracts at an earlier age as compared to the unaffected population.


Currently, there is no treatment to stop a person with Cone Rod Dystrophy (CRD) from losing their vision. Possible future treatments for CRD may include gene therapy, stem cell therapy, and retinal implants. The beta-carotenoids, lutein and zeaxanthin, have been evidenced to reduce the risk of developing to Cone dystrophy sufferers.


The Global Cone-Rod Dystrophy Market is expected to grow at a CAGR of approximately 5.3% during the forecast period 2017-2023.


Intended Audience



  • Cone Rod Dystrophy Supplement Suppliers

  • Cone Rod Dystrophy Drug Manufacturers

  • Research and Development (R&D) Companies

  • Medical Research Laboratories

  • Academic Medical Institutes and Universities


Key Players


Some of key the players in the global cone-rod dystrophy market are GlaxoSmithKline Plc. (U.S.), Johnson & Johnson (U.S.), Sanofi (Switzerland), Pfizer Inc. (U.S.), Novartis AG (Switzerland), Abbott Laboratories (U.S.), Sunovion Pharmaceuticals (U.S.), Cephalon (U.S.),  DSM (India), Amway (U.S.), Vitamin Shoppe (U.S.), Intas Pharmaceutials Limited (India), Sun Pharmaceuticals Ltd. (India) Emcure Pharmaceuticals Limited (India),  Nutrilite (U.S.), NutraScience Labs (U.S.), and others.


Research Methodology Cone Rod Dystrophy Market


Sources: Annual reports, Press release, White paper, and Company presentation


Segmentation


The cone rod dystrophy is segmented on the basis of diagnosis, treatment, and end-users.


On the basis of the diagnosis, the market is segmented into electroretinogram (ERG), clinical history, fundus examination, molecular diagnosis, and others.


On the basis of the treatment, the market is segmented into tinted lenses/ dark sunglass, medications, magnifying devices, and surgery. The medication is classified into vitamin A supplement and anticonvulsant.


On the basis of the end-user, the market is segmented into hospitals, ophthalmic centers, research organizations, and academic institutes.


Regional Analysis


The global cone-rod dystrophy market consists of countries namely America, Europe, Asia Pacific, and the Middle East and Africa.


The Americas is projected to hold the largest share of the global cone rod dystrophy market due to the increasing eye disorders in the U.S.  According to American Academy of Ophthalmology, over 10 million laser eye surgery procedures are performed in the U.S. each year with a satisfaction rate of 95.4%. Majority of people prefer ophthalmic clinics rather than hospitals. Besides this, increasing number of ophthalmic clinics across the globe has led to increase the market. According to the International Council of Ophthalmology, there are approximately 213,459 ophthalmologists worldwide of which around 19,216 are present in the U.S.


The European region is expected to be the second largest market over the forecast period owing to substantial technological advancements. According to the National Organization for Rare Disorders (NORD), the estimated incidence of the disorder is approximately 1 in 30,000 individuals in the general population. Cone dystrophy is usually present in early infancy or during childhood or early adulthood. However, the disorder has been reported to develop in individuals of all ages including older adults.


The market in the Asia Pacific is expected to witness the fastest growth rate within the forecast period due to increasing geriatric population coupled with rising cases of ocular genetic disorders. The Middle East and Africa are also expected to grow considerably less over the forecast period.



Frequently Asked Questions (FAQ) :


The cone rod dystrophy market projected to grow at a 5.3% CAGR between 2018-2023.

The Americas is expected to dominate the cone rod dystrophy market.

Major end users of the cone rod dystrophy market include academic institutes, research organizations, ophthalmic centers, and hospitals.

Key players profiled in the cone rod dystrophy market include NutraScience Labs (U.S.), Nutrilite (U.S.), Emcure Pharmaceuticals Limited (India), Sun Pharmaceuticals Ltd. (India), Intas Pharmaceutials Limited (India), Vitamin Shoppe (U.S.), Amway (U.S.), DSM (India), Cephalon (U.S.), Sunovion Pharmaceuticals (U.S.), Abbott Laboratories (U.S.), Novartis AG (Switzerland), Pfizer Inc. (U.S.), Sanofi (Switzerland), Johnson & Johnson (U.S.), and GlaxoSmithKline Plc (U.S.).

Strategies adopted by key players to stay ahead in the cone rod dystrophy market include strategic alliances, joint ventures, new product launches, and acquisitions.

TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Cone rod dystrophy Market, by Diagnosis

6.1 Introduction

6.2 Electroretinogram (ERG)

6.2.1 Market Estimates & Forecast, 2020 – 2027

6.3 Clinical history

6.3.1 Market Estimates & Forecast, 2020 – 2027

6.4 Fundus examination

6.4.1 Market Estimates & Forecast, 2020 – 2027

6.5 Molecular diagnosis

6.5.1 Market Estimates & Forecast, 2020 – 2027

6.5 Others

Chapter 7. Global Cone rod dystrophy Market, by Treatment

7.1 Introduction

7.2 Tinted lenses/ dark sunglass

7.2.1 Market Estimates & Forecast, 2020 – 2027

7.3 Medications

7.3.1 Market Estimates & Forecast, 2020 – 2027

7.3.2 Vitamin A supplement

7.3.2.1 Market Estimates & Forecast, 2020 – 2027

7.3.3 Anticonvulsant

7.3.3.1 Market Estimates & Forecast, 2020 – 2027

7.4 Magnifying devices

7.4.1 Market Estimates & Forecast, 2020 – 2027

7.5 Surgery

7.5.1 Market Estimates & Forecast, 2020 – 2027

Chapter 8. Global Cone rod dystrophy Market, by End User

8.1 Introduction

8.2 Hospitals

8.2.1 Market Estimates & Forecast, 2020 – 2027

8.3 Ophthalmic centers

8.3.1 Market Estimates & Forecast, 2020 – 2027

8.4 Research organizations

8.4.1 Market Estimates & Forecast, 2020 – 2027

8.5 Academic institutes

8.5.1 Market Estimates & Forecast, 2020 – 2027

Chapter. 9 Global Cone rod dystrophy Market, by Region

9.1 Introduction

9.2 Americas

9.2.1 North America

9.2.1.1 U.S.

9.2.1.1 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 Italy

9.3.1.4 Spain

9.3.1.5 U.K

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 Republic of Korea

9.4.6 Rest of Asia Pacific

9.5 The Middle East & Africa

9.5.1 United Arab Emirates

9.5.2 Saudi Arabia

9.5.3 Rest of the Middle East & Africa

Chapter 10 Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

10.3.1 Key Developments

Chapter 11 Company Profiles

11.1 GlaxoSmithKline Plc

11.1.1 Company Overview

11.1.2 Treatment Overview

11.1.3 Financials

11.1.4 SWOT Analysis

11.2 Johnson & Johnson

11.2.1 Company Overview

11.2.2 Treatment Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 Sanofi

11.3.1 Company Overview

11.3.2 Treatment Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 Pfizer Inc.

11.4.1 Company Overview

11.4.2 Treatment/Business Segment Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 Novartis AG

11.5.1 Company Overview

11.5.2 Treatment Overview

11.5.3 Financial overview

11.5.4 Key Developments

11.6 Abbott Laboratories

11.6.1 Company Overview

11.6.2 Treatment Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.7 Sunovion Pharmaceuticals

11.7.1 Overview

11.7.2 Treatment Overview

11.7.3 Financials

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 Cephalon

11.8.1 Company Overview

11.8.2 Treatment/Business Segment Overview

11.8.3 Financial Overview

11.8.4 Key Development

11.8.5 SWOT Analysis

11.9 DSM

11.9.1 Company Overview

11.9.2 Treatment Overview

11.9.3 Financial overview

11.9.4 Key Developments

11.10 Vitamin Shoppe

11.10.1 Company Overview

11.10.2 Treatment/Business Segment Overview

11.10.3 Financial Overview

11.10.4 Key Development

11.10.5 SWOT Analysis

11.11 Intas Pharmaceutials Limited

11.11.1 Company Overview

11.11.2 Treatment Overview

11.11.3 Financial overview

11.11.4 Key Developments

11.12 Sun Pharmaceuticals Ltd.

11.12.1 Company Overview

11.12.2 Treatment/Business Segment Overview

11.12.3 Financial Overview

11.12.4 Key Development

11.12.5 SWOT Analysis

11.13 Emcure Pharmaceuticals Limited

11.13.1 Company Overview

11.13.2 Treatment Overview

11.13.3 Financial overview

11.13.4 Key Developments

11.14 Nutrilite

11.14.1 Company Overview

11.14.2 Treatment/Business Segment Overview

11.14.3 Financial Overview

11.14.4 Key Development

11.14.5 SWOT Analysis

11.15 NutraScience Labs

11.15.1 Company Overview

11.15.2 Treatment Overview

11.15.3 Financial overview

11.15.4 Key Developments

11.16 Others

Chapter 12 MRFR Conclusion

12.1 Key Findings

12.1.1 From CEO’s View Point

12.1.2 Unmet Needs of the Market

12.2 Key Companies to Watch

12.3 Prediction of Pharmaceutical industry

Chapter 13 Appendix

LIST OF TABLES

Table 1 Cone rod dystrophy Industry Synopsis, 2020 – 2027

Table 2 Cone rod dystrophy Market Estimates and Forecast, 2020 – 2027, (USD Million)

Table 3 Cone rod dystrophy Market by Region, 2020 – 2027, (USD Million)

Table 4 Cone rod dystrophy Market by Diagnosis, 2020 – 2027, (USD Million)

Table 5 Cone rod dystrophy Market by Treatment, 2020 – 2027, (USD Million)

Table 6 Cone rod dystrophy Market by End Users, 2020 – 2027, (USD Million)

Table 7 North America Cone rod dystrophy Market by Diagnosis, 2020 – 2027, (USD Million)

Table 8 North America Cone rod dystrophy Market by Treatment, 2020 – 2027, (USD Million)

Table 9 North America Cone rod dystrophy Market by End User, 2020 – 2027, (USD Million)

Table 10 US Cone rod dystrophy Market by Diagnosis, 2020 – 2027, (USD Million)

Table 11 US Cone rod dystrophy Market by Treatment, 2020 – 2027, (USD Million)

Table 12 US Cone rod dystrophy Market by End User, 2020 – 2027, (USD Million)

Table 13 Canada Cone rod dystrophy Market by Diagnosis, 2020 – 2027, (USD Million)

Table 14 Canada Cone rod dystrophy Market by Treatment, 2020 – 2027, (USD Million)

Table 15 Canada Cone rod dystrophy Market by End User, 2020 – 2027, (USD Million)

Table 16 South America Cone rod dystrophy Market by Diagnosis, 2020 – 2027, (USD Million)

Table 17 South America Cone rod dystrophy Market by Treatment, 2020 – 2027, (USD Million)

Table 18 South America Cone rod dystrophy Market by End User, 2020 – 2027, (USD Million)

Table 19 Europe Cone rod dystrophy Market by Diagnosis, 2020 – 2027, (USD Million)

Table 20 Europe Cone rod dystrophy Market by Treatment, 2020 – 2027, (USD Million)

Table 21 Europe Cone rod dystrophy Market by End User, 2020 – 2027, (USD Million)

Table 22 Western Europe Cone rod dystrophy Market by Diagnosis, 2020 – 2027, (USD Million)

Table 23 Western Europe Cone rod dystrophy Market by Treatment, 2020 – 2027, (USD Million)

Table 24 Western Europe Cone rod dystrophy Market by End User, 2020 – 2027, (USD Million)

Table 25 Eastern Europe Cone rod dystrophy Market by Diagnosis, 2020 – 2027, (USD Million)

Table 26 Eastern Europe Cone rod dystrophy Market by Treatment, 2020 – 2027, (USD Million)

Table 27 Eastern Europe Cone rod dystrophy Market by End User, 2020 – 2027, (USD Million)

Table 28 Asia Pacific Cone rod dystrophy Market by Diagnosis, 2020 – 2027, (USD Million)

Table 29 Asia Pacific Cone rod dystrophy Market by Treatment, 2020 – 2027, (USD Million)

Table 30 Asia Pacific Cone rod dystrophy Market by End User, 2020 – 2027, (USD Million)

Table 31 The Middle East & Africa Cone rod dystrophy Market by Diagnosis, 2020 – 2027, (USD Million)

Table 32 The Middle East & Africa Cone rod dystrophy Market by Treatment, 2020 – 2027, (USD Million)

Table 33 The Middle East & Africa Cone rod dystrophy Market by End User, 2020 – 2027, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Cone rod dystrophy Market

Figure 3 Segmentation Market Dynamics for Cone rod dystrophy Market

Figure 4 Global Cone rod dystrophy Market Share, by Diagnosis 2020

Figure 5 Global Cone rod dystrophy Market Share, by Treatment 2020

Figure 6 Global Cone rod dystrophy Market Share, by End Users, 2020

Figure 7 Global Cone rod dystrophy Market Share, by Region, 2020

Figure 8 North America Cone rod dystrophy Market Share, by Country, 2020

Figure 9 Europe Cone rod dystrophy Market Share, by Country, 2020

Figure 10 Asia Pacific Cone rod dystrophy Market Share, by Country, 2020

Figure 11 The Middle East & Africa Cone rod dystrophy Market Share, by Country, 2020

Figure 12 Global Cone rod dystrophy Market: Company Share Analysis, 2020 (%)

Figure 13 GlaxoSmithKline Plc: Key Financials

Figure 14 GlaxoSmithKline Plc: Segmental Revenue

Figure 15 GlaxoSmithKline Plc: Geographical Revenue

Figure 16 Johnson & Johnson: Key Financials

Figure 17 Johnson & Johnson: Segmental Revenue

Figure 18 Johnson & Johnson: Geographical Revenue

Figure 19 Sanofi: Key Financials

Figure 20 Sanofi: Segmental Revenue

Figure 22 Sanofi: Geographical Revenue

Figure 23 Pfizer Inc.: Key Financials

Figure 24 Pfizer Inc.: Segmental Revenue

Figure 25 Pfizer Inc.: Geographical Revenue

Figure 27 Novartis AG: Key Financials

Figure 28 Novartis AG: Segmental Revenue

Figure 29 Novartis AG: Geographical Revenue

Figure 30 Abbott Laboratories: Key Financials

Figure 32 Abbott Laboratories: Segmental Revenue

Figure 33 Abbott Laboratories: Geographical Revenue

Figure 33 Sunovion Pharmaceuticals: Key Financials

Figure 34 Sunovion Pharmaceuticals: Segmental Revenue

Figure 35 Sunovion Pharmaceuticals: Geographical Revenue

Figure 36 Cephalon: Key Financials

Figure 37 Cephalon: Segmental Revenue

Figure 38 Cephalon: Geographical Revenue

Figure 39 DSM: Key Financials

Figure 40 DSM: Segmental Revenue

Figure 41 DSM: Geographical Revenue

Figure 42 Amway: Key Financials

Figure 43 Amway: Segmental Revenue

Figure 44 Amway: Geographical Revenue

Figure 45 Vitamin Shoppe: Key Financials

Figure 46 Vitamin Shoppe: Segmental Revenue

Figure 47 Vitamin Shoppe: Geographical Revenue

Figure 48 Intas Pharmaceutials Limited: Key Financials

Figure 49 Intas Pharmaceutials Limited: Segmental Revenue

Figure 50 Intas Pharmaceutials Limited: Geographical Revenue

Figure 51 Sun Pharmaceuticals Ltd: Key Financials

Figure 52 Sun Pharmaceuticals Ltd: Segmental Revenue

Figure 53 Sun Pharmaceuticals Ltd: Geographical Revenue

Figure 54 Emcure Pharmaceuticals Limited: Key Financials

Figure 55 Emcure Pharmaceuticals Limited: Segmental Revenue

Figure 56 Emcure Pharmaceuticals Limited: Geographical Revenue

Figure 57 Nutrilite: Key Financials

Figure 58 Nutrilite: Segmental Revenue

Figure 59 Nutrilite: Geographical Revenue

Figure 60 NutraScience Labs: Key Financials

Figure 61 NutraScience Labs: Segmental Revenue

Figure 62 NutraScience Labs: Geographical Revenue